Raina Setzer knows the work she does matters. That’s because she’s already seen it from the other side. Setzer, a radiochemical processing technician in Oak Ridge National Laboratory’s Isotope Processing and Manufacturing Division, joined the lab in June 2023.
Researchers at ORNL explored radium’s chemistry to advance cancer treatments using ionizing radiation.
As a medical isotope, thorium-228 has a lot of potential — and Oak Ridge National Laboratory produces a lot.
A rare isotope in high demand for treating cancer is now more available to pharmaceutical companies developing and testing new drugs.
When Sandra Davern looks to the future, she sees individualized isotopes sent into the body with a specific target: cancer cells.
Oak Ridge National Laboratory researchers have discovered a better way to separate actinium-227, a rare isotope essential for an FDA-approved cancer treatment.
In the 1960s, Oak Ridge National Laboratory's four-year Molten Salt Reactor Experiment tested the viability of liquid fuel reactors for commercial power generation. Results from that historic experiment recently became the basis for the first-ever molten salt reactor benchmark.
Scientists from Oak Ridge National Laboratory performed a corrosion test in a neutron radiation field to support the continued development of molten salt reactors.
Experts focused on the future of nuclear technology will gather at Oak Ridge National Laboratory for the fourth annual Molten Salt Reactor Workshop on October 3–4.
The Department of Energy’s Oak Ridge National Laboratory is now producing actinium-227 (Ac-227) to meet projected demand for a highly effective cancer drug through a 10-year contract between the U.S. DOE Isotope Program and Bayer.